# Junta clínica — PT-pseudo_2eef4115a253 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2eef4115a253",
  "pid": "PT-pseudo_2eef4115a253",
  "task": 1,
  "psa": 2.11,
  "age": 59,
  "months": 1,
  "pirads": "4",
  "psad": 0.058,
  "psav": -0.04,
  "psap": 2.1,
  "vol": 36.08,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.7737494,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 2.11 ng/mL. PI-RADS 4. PSAD 0.06. Prostate volume 36 mL. csPCa 0.77.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "85 kg",
    "height": "182 cm",
    "bmi": "25.7",
    "bp": "117/84 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (36 pack-yr, quit 2021)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Evaluation requested after imaging revealed a left peripheral zone abnormality alongside a recent PSA elevation."
    },
    {
      "s": "History",
      "t": "At 59 years of age, the patient works as a retired shopkeeper. He is divorced and currently resides with his partner. A former smoker, he accumulated 36 pack-years before cessation in 2021. Daily activity remains largely sedentary, punctuated by brief walks. Moderate voiding complaints dominate the history, specifically nocturia and a diminished urinary stream, correlating with an IPSS score of 19. He explicitly denies haematuria or pelvic discomfort. No chronic comorbidities exist, and he takes no active medications. Alcohol intake averages two units per week. An Arabic interpreter will be required during the consultation to facilitate precise dialogue."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: symmetrically smooth; consistency: normal; asymmetry: absent; nodules: none. Vital parameters remain stable, recording a blood pressure of 117/84 mmHg alongside a regular heart rate of 73 bpm. Thoracic auscultation reveals clear lung fields, and no peripheral oedema is observed."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Pulmonary function test — known COPD follow-up",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "2 units / week",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 19/35 (moderate LUTS)",
  "admin": "Interpreter (Arabic) requested for next visit.",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2eef4115a253
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 2.11 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.058 ng/mL²
  - PSA velocity: -0.04 ng/mL/yr
  - Prior PSA: 2.1 ng/mL
  - Prostate volume: 36.08 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7737494 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 2.11 ng/mL. PI-RADS 4. PSAD 0.06. Prostate volume 36 mL. csPCa 0.77.

Vitals: weight 85 kg, height 182 cm, BMI 25.7, BP 117/84 mmHg, HR 73 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2021).

Chief complaint: Evaluation requested after imaging revealed a left peripheral zone abnormality alongside a recent PSA elevation.

History: At 59 years of age, the patient works as a retired shopkeeper. He is divorced and currently resides with his partner. A former smoker, he accumulated 36 pack-years before cessation in 2021. Daily activity remains largely sedentary, punctuated by brief walks. Moderate voiding complaints dominate the history, specifically nocturia and a diminished urinary stream, correlating with an IPSS score of 19. He explicitly denies haematuria or pelvic discomfort. No chronic comorbidities exist, and he takes no active medications. Alcohol intake averages two units per week. An Arabic interpreter will be required during the consultation to facilitate precise dialogue.

Physical examination: DRE — texture: symmetrically smooth; consistency: normal; asymmetry: absent; nodules: none. Vital parameters remain stable, recording a blood pressure of 117/84 mmHg alongside a regular heart rate of 73 bpm. Thoracic auscultation reveals clear lung fields, and no peripheral oedema is observed.

Patient info: retired shopkeeper; Divorced; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Vascular surgery — varicose veins consult.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.42
  uncertainty  +/- 0.18 (95% CI 0.08-0.77); among patients it cannot tell apart the outcome was 0.98 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that combining targeted biopsy with perilesional sampling is recommended when MRI is positive (i.e., PI-RADS $\ge 4$).

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of 'NO BIOPSY' is not sufficiently informed by the guideline because it does not account for the specific risk stratification provided by the PI-RADS score. The guideline sets a threshold of PI-RADS $\ge 3$ to trigger biopsy, which is a variable the classifier could not fully weigh. Furthermore, the classifier's bid does not incorporate the guideline's recommendation to combine targeted biopsy with perilesional sampling when the PI-RADS is $\ge 4$.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose states the lesion is a left peripheral zone abnormality, which is a finding that the guideline makes decisive regarding the need for biopsy.
The PSA trend - the PSA velocity is -0.04 ng/mL/yr, which is a finding that the guideline makes decisive regarding the need for biopsy.
The previous notes - the previous notes state "Prior biopsy: None," which is a finding that the guideline makes decisive regarding the need for biopsy.
The laboratory results - the PSA density is 0.058 ng/mL², which is a finding that the guideline makes decisive regarding the need for biopsy.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on the specific interpretation of the mpMRI prose, the PSA trend, and the previous notes to determine the next step according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose regarding the left peripheral zone abnormality and any comparison to earlier studies.
  psa_trend (get_psa_trend) -> Determine the significance of the PSA velocity (-0.04 ng/mL/yr) in the context of the guideline.
  previous_notes (get_previous_notes) -> Confirm the management context, specifically the status of the prior biopsy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the left peripheral zone abnormality?
  Q2. What does the PSA trend indicate regarding the need for biopsy?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states: "A roughly 12 mm focal hypointense area occupies the left peripheral zone at mid-gland level. T2-weighted sequences highlight this region. Diffusion-weighted imaging shows marked restriction, confirmed by low apparent diffusion coefficient signals. Dynamic contrast studies demonstrate early, focal enhancement compared to adjacent tissue."
psa_trend
The PSA velocity is -0.04 ng/mL/yr, which is a decreasing trend.
previous_notes
The previous notes confirm the management context by stating: "Prior biopsy: None".

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them in the plan, and the key findings regarding PSA density were already present in the structured panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report finding of a PI-RADS 4 lesion in the left peripheral zone.
Previous notes confirming "Prior biopsy: None".
AGAINST sampling this patient now
PSA trend showing a decreasing velocity (-0.04 ng/mL/yr).

WHERE THIS LEANS
The combination of a PI-RADS 4 finding, no prior biopsy, and a recent PSA elevation leans towards proceeding with biopsy according to the EAU guideline.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 and Q2 by opening the `radiology_report` and `psa_trend`, which directly address the moderator's questions.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-EAU's reasoning by confirming the PI-RADS 4 finding (from the report) and the lack of prior biopsy (from previous notes), which supports the guideline's recommendation for biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the left peripheral zone abnormality? Answered by the registrar via the `radiology_report`: "A roughly 12 mm focal hypointense area occupies the left peripheral zone at mid-gland level. T2-weighted sequences highlight this region. Diffusion-weighted imaging shows marked restriction, confirmed by low apparent diffusion coefficient signals. Dynamic contrast studies demonstrate early, focal enhancement compared to adjacent tissue."
Q2. What does the PSA trend indicate regarding the need for biopsy? Answered by the registrar via the `psa_trend`: "The PSA velocity is -0.04 ng/mL/yr, which is a decreasing trend."

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score ($\ge 4$ triggers biopsy), the prior biopsy status (no prior biopsy), and the presence of a lesion in the peripheral zone. The PI-RADS 4 finding is critical because the guideline explicitly recommends combined biopsy/perilesional sampling for PI-RADS $\ge 4$. The decreasing PSA velocity is a factor that might temper the urgency but does not negate the high-risk imaging finding. The variable the room leaned on that the guideline does not support is the decreasing PSA velocity as a sole determinant.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with biopsy, as the combination of a PI-RADS 4 lesion in the peripheral zone and no prior biopsy strongly supports the guideline recommendation for intervention.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is driven by the PI-RADS 4 finding in the left peripheral zone, which is a decisive factor according to the EAU guideline. This is strongly supported by the cohort criterion, which matched the reading urologist in all cases of this presentation. The lack of a prior biopsy further supports the need for tissue sampling to establish a diagnosis. Although the PSA velocity was decreasing, the high-risk imaging finding outweighs this factor.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
